Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026

Written by Luis Rodriguez on 21st February 2026. Posted in Client News.

[image_slider_no_space on_click=”prettyphoto” height=”600″ navigation_style=”light” images=”940,950,954,952,953,951″]